ABBV-221 is an antibody drug conjugate (ADC) targeting EGFR that is being investigated to treat cancerous tumors.

Type of Molecule

Biologic

Target

EGFR

Region

n/a

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Solid Tumors New Indication Phase 1